Market capitalization | $47.46m |
Enterprise Value | $74.72m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 1.03 |
P/S ratio (TTM) P/S ratio | 0.65 |
P/B ratio (TTM) P/B ratio | 4.78 |
Revenue growth (TTM) Revenue growth | 5.03% |
Revenue (TTM) Revenue | $72.71m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
4 Analysts have issued a Neuronetics, Inc. forecast:
4 Analysts have issued a Neuronetics, Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 73 73 |
5%
5%
|
|
Gross Profit | 53 53 |
11%
11%
|
|
EBITDA | -25 -25 |
19%
19%
|
EBIT (Operating Income) EBIT | -28 -28 |
17%
17%
|
Net Profit | -36 -36 |
10%
10%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
Head office | United States |
CEO | Keith Sullivan |
Employees | 203 |
Founded | 1998 |
Website | www.neurostar.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.